Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
16.78
-0.75 (-4.28%)
At close: May 30, 2025, 4:00 PM
16.79
+0.01 (0.06%)
After-hours: May 30, 2025, 7:54 PM EDT

Teva Pharmaceutical Statistics

Total Valuation

Teva Pharmaceutical has a market cap or net worth of $19.25 billion. The enterprise value is $34.49 billion.

Market Cap 19.25B
Enterprise Value 34.49B

Important Dates

The last earnings date was Wednesday, May 7, 2025, before market open.

Earnings Date May 7, 2025
Ex-Dividend Date n/a

Share Statistics

Teva Pharmaceutical has 1.15 billion shares outstanding. The number of shares has increased by 1.23% in one year.

Current Share Class n/a
Shares Outstanding 1.15B
Shares Change (YoY) +1.23%
Shares Change (QoQ) +2.29%
Owned by Insiders (%) 0.41%
Owned by Institutions (%) 74.71%
Float 1.14B

Valuation Ratios

PE Ratio n/a
Forward PE 6.53
PS Ratio 1.15
Forward PS 1.44
PB Ratio 3.07
P/TBV Ratio n/a
P/FCF Ratio 25.16
P/OCF Ratio 15.20
PEG Ratio 0.81
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.75, with an EV/FCF ratio of 45.08.

EV / Earnings n/a
EV / Sales 2.08
EV / EBITDA 7.75
EV / EBIT 10.08
EV / FCF 45.08

Financial Position

The company has a current ratio of 1.03, with a Debt / Equity ratio of 2.70.

Current Ratio 1.03
Quick Ratio 0.46
Debt / Equity 2.70
Debt / EBITDA 3.69
Debt / FCF 22.14
Interest Coverage 3.46

Financial Efficiency

Return on equity (ROE) is -19.11% and return on invested capital (ROIC) is 8.44%.

Return on Equity (ROE) -19.11%
Return on Assets (ROA) 5.27%
Return on Invested Capital (ROIC) 8.44%
Return on Capital Employed (ROCE) 12.55%
Revenue Per Employee $451,154
Profits Per Employee -$34,917
Employee Count 36,830
Asset Turnover 0.41
Inventory Turnover 2.35

Taxes

In the past 12 months, Teva Pharmaceutical has paid $802.00 million in taxes.

Income Tax 802.00M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +2.01% in the last 52 weeks. The beta is 0.63, so Teva Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y) 0.63
52-Week Price Change +2.01%
50-Day Moving Average 15.64
200-Day Moving Average 17.54
Relative Strength Index (RSI) 51.37
Average Volume (20 Days) 14,065,381

Short Selling Information

Short Interest 38.70M
Short Previous Month 30.34M
Short % of Shares Out 3.39%
Short % of Float n/a
Short Ratio (days to cover) 2.95

Income Statement

In the last 12 months, Teva Pharmaceutical had revenue of $16.62 billion and -$1.29 billion in losses. Loss per share was -$1.14.

Revenue 16.62B
Gross Profit 8.17B
Operating Income 3.42B
Pretax Income 131.00M
Net Income -1.29B
EBITDA 4.45B
EBIT 3.42B
Loss Per Share -$1.14
Full Income Statement

Balance Sheet

The company has $1.70 billion in cash and $16.94 billion in debt, giving a net cash position of -$15.24 billion or -$13.29 per share.

Cash & Cash Equivalents 1.70B
Total Debt 16.94B
Net Cash -15.24B
Net Cash Per Share -$13.29
Equity (Book Value) 6.27B
Book Value Per Share 5.46
Working Capital 371.00M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $1.27 billion and capital expenditures -$501.00 million, giving a free cash flow of $765.00 million.

Operating Cash Flow 1.27B
Capital Expenditures -501.00M
Free Cash Flow 765.00M
FCF Per Share $0.67
Full Cash Flow Statement

Margins

Gross margin is 49.16%, with operating and profit margins of 20.59% and -7.74%.

Gross Margin 49.16%
Operating Margin 20.59%
Pretax Margin -3.12%
Profit Margin -7.74%
EBITDA Margin 26.79%
EBIT Margin 20.59%
FCF Margin 4.60%

Dividends & Yields

Teva Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -1.23%
Shareholder Yield -1.23%
Earnings Yield -6.68%
FCF Yield 3.97%
Dividend Details

Analyst Forecast

The average price target for Teva Pharmaceutical is $25.14, which is 49.82% higher than the current price. The consensus rating is "Strong Buy".

Price Target $25.14
Price Target Difference 49.82%
Analyst Consensus Strong Buy
Analyst Count 7
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on July 1, 2004. It was a forward split with a ratio of 2:1.

Last Split Date Jul 1, 2004
Split Type Forward
Split Ratio 2:1

Scores

Teva Pharmaceutical has an Altman Z-Score of 0.56 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 0.56
Piotroski F-Score 7